Scientists analyze genetic characteristics of cancers using multiple genomics technology platforms

Scientists analyze genetic characteristics of cancers using multiple genomics technology platforms -

New research conducted by scientists affiliated partly UC San Francisco suggests that the one of 10 cancer patients will be diagnosed more accurately if their tumors were defined by cellular and molecular criteria rather than the tissue in which they originate, and this information, in turn, could lead to treatments most appropriate.

in the largest study of its kind to date, the scientists analyzed the molecular and genetic characteristics of more than 3,500 samples of tumors from 12 different cancer types using multiple technology platforms genomics.

cancers traditionally have been classified by their 'tissue of origin "-like breast, bladder or kidney cancer. But the tissues are composed of different types of cells, and new research indicates that, in many cases, the type of cells affected by cancer can be a useful guide to treatment than the tissue in which tumor originated.

the study, published August 7, 2014 publishing line of the cell was conducted under the initiative cancer genome Atlas (TCGA) conducted by the National cancer Institute and the National Institute for research on the human genome, both part of the National Institutes of Health.

in the new work, TCGA research network of scientists analyzed the DNA, RNA and proteins from tumor types 12 using six different genomic technologies to see how different tumor types compare to each other. The team arrived at a rating based on 12 sub-types of cancer. Five of them were consistent with classifications tissue of origin, but several newly identified subtypes were seen affecting a variety of fabrics.

"This genomic challenges not only our current system study cancer classification based on tissue type, but also provides a huge new resource data for further exploration, and a comprehensive list of features molecular distinguishing each of the newly described class of cancer, "said co-lead author Christopher Benz, MD, professor at the Buck Institute for research on aging, assistant professor of medicine at UCSF, and Helen Diller family member Comprehensive Cancer Center at UCSF.

particularly striking results were seen in cancers of the bladder and breast. At least three different subtypes of bladder cancer were identified, one virtually indistinguishable from lung adenocarcinomas, and another more similar to squamous cell cancers of the head and neck and lung. (In the new study, these squamous cell cancers seemed to form their own sub-type, whether they originate in the lung or head and neck.) The results may help explain why patients with bladder cancer "react often differently when treated with the same systemic therapy for their type of cancer apparently identical, "said Benz.

study also confirmed the known differences between the subtypes of breast cancer known as "luminal cancers" basal-like "and". But because the researchers compared these cancers not only with each other but with many other types of cancer, they were able to reveal that these differences are very deep, and basal-like breast cancers are their own distinct class. "What is amazing is that the basal breast cancer is also different from a luminal breast cancer as it is, say, kidney cancer," said co-lead author Denise Wolf, PhD, a researcher based at the Department laboratory medicine UCSF.

Commonly called "triple negative" basal-like cancers are aggressive, are more common in African American women and young women. "Although these basal-like cancers occur in the chest, at the molecular level, they have more in common with cancer and squamous cancers original than other subtypes of ovarian breast cancer," said co-author Christina Yau, Ph.D., a scientist Buck Institute's staff and assistant professor of surgery at UCSF.

TCGA was launched in 06 to compile genomic atlas more than 20 types of cancer. as the project progressed, however, the similarities between the types of cancer began to emerge, which led to the creation of TCGA project "Pan-cancer," the source of the data used in the new study.

"This is the first time you've been able to indicate important molecular features shared by the basal breast cancer, and cancer of the head and neck squamous and lung cancer," said Wolf. "And the same is true of immune activation, we found that different types of cancer have very similar immune signatures, a factor that may be clinically relevant with the rise of new immune therapies."

Benz thinks the number of patients eligible for reclassification will swell when multiple tumor samples and additional types of tumors are included in the next round of the Pan-Cancer project analysis, which should include more than 20 different types of tumors . "We'll just enjoy the tip of the iceberg when considering the potential of this type of multi-platform genome analysis," said Benz. "It could be up to 30 or 50 percent of cancers are reclassified."

Benz hope that these studies will feed into the design of clinical trials on genomics reclassification base tumors that patients become eligible for new therapies. "Although follow-up studies are needed to validate and refine the classification system of the newly proposed cancer," Benz said, "it will ultimately provide the biological basis for personalized treatment of the time cancer patients and clinicians look forward to. "

light research discounts the role of hepatic mTORC1 in the physiology of body

light research discounts the role of hepatic mTORC1 in the physiology of body -

The protein mTOR is a central controller for growth and metabolism. Dysregulation of mTOR signaling increases the risk of developing metabolic diseases such as diabetes, obesity and cancer. In the current issue of Proceedings of the National Academy of Sciences , the Basel Biozentrum of the University researchers describe how aberrant mTOR signaling in the liver not only affects the liver metabolism, but also the entire physiology of the body.

mTOR regulates cell growth and metabolism and therefore plays a key role in the development of human diseases. In the cell, the regulatory protein is located in two complexes of structurally and functionally distinct proteins called mTORC1 and mTORC2. In a recent study, the group of Prof. Michael Hall of the Biozentrum, University of Basel research has highlighted the role of mTORC1 in liver physiology of the entire body and the relevance to human liver cancers.

hepatic mTORC1 control body physiology

in mammals, the liver is a key member which controls the entire physiology of the body in response to nutrients. The Hall team investigated the role of mTORC1 nutrient sensor in the process. The researchers were able to show that the activation of mTORC1 in livers of mice not only reduces hepatic lipid metabolism, but also the locomotor activity and body temperature. After investigation of the underlying molecular mechanism, they observed that mTORC1 hyperactivation improves the level of the stress hormone FGF21 by the loss of glutamine, an amino acid. Treatment of animals with glutamine reduced the level of FGF21 and thus avoids the physiological impairments.

Cancer treatment with mTORC1 inhibitors

human cancers often exhibit aberrant mTORC1 signaling and glutamine addiction. "We were delighted to see that in the human liver tumors mTORC1 signaling correlates with the expression of FGF21" cell biologist Dr. Marion comments Cornu and first author of the study. Furthermore, mTORC1 inhibitors such as Rapamycin are presently used as immunosuppressive agents and anti-cancer drugs. Thus, new discoveries of Hall team provide evidence that the treatment of human cancers with glutamine addicted rapamycin could have beneficial effects in blocking tumor growth and preventing the deregulation of the whole body physiology .

colon cancer screening test wins FDA approval

colon cancer screening test wins FDA approval -

The test, called Cologuard, can detect genetic mutations in stool samples of patients that are associated cancerous and precancerous tumors.

The Wall Street Journal: The FDA approves DNA test for colon cancer
The Food and Drug Administration on Monday approved a DNA test to detect colon cancer in people with a lower risk of developing the disease, the first such test of its kind to be approved by US regulators. The test, called Cologuard, is used to detect genetic mutations in the stool of patients associated with cancer and precancerous growths in the colon. Doctors must prescribe the test, but patients collect stool samples at home and send samples to laboratories for analysis (Walker, 8/11)

Pioneer Press. Mayo-Backed Colon Screening Tests Gets FDA Approval
Food and Drug Administration announced Monday approval for Cologuard, a new test kit developed in part at the Mayo Clinic for patient screening to assess their risk colorectal cancer. In a related announcement on Monday, the federal Centers for Medicare and Medicaid Services has proposed that the federal Medicare cover the costs for the new test. Colorectal cancer mainly affects people aged 50 and over and is one of the most common causes of cancer deaths (Snowbeck, 8/11)

Bloomberg :. Exact Sciences of the United States wins approval for Colon cancer test
the Food and Drug Administration manages Cologard, which screens stool samples for the presence of red blood cells and DNA mutations that can indicate the presence of cancer. Patients use the Exact Sciences test of Wisconsin Madison, the house and those with positive results are invited to get a colonoscopy, which uses a small video camera at the end of a thin tube to view the colon, FDA said yesterday in a statement (Edney, 8/12).

---

This article has been reprinted kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a professional health policy research non-partisan organization affiliated with Kaiser Permanente.

MicroVAX begin Phase I clinical trials for the exclusive platform of vaccine against cancer

MicroVAX begin Phase I clinical trials for the exclusive platform of vaccine against cancer -

MicroVAX, LLC, a biotechnology company based in Manassas, Virginia announced today the start of a phase I trial for its platform sole and exclusive vaccine that under the provisions of an entry FDA IND patients with breast, prostate, colon, ovarian and lung cancer, who have relapsed after initial salvage therapy.

The trial is sponsored by the Singapore Clinical Research Institute (SCRI), and led by Dr Toh Han Chong, Senior Advisor and Deputy Director of the National Cancer Centre Singapore (NCCS). "Our main objective is to evaluate the safety and benefits of this unique vaccine, designed to target a protein common to most of the more common cancers such as colon cancer, breast cancer and cancer of the ovary, and to provide specific additional boost to the immune system against cancer at the same time. We will also evaluate how powerful this vaccine can stimulate a significant immune response against cancer. " When fully implemented, the MicroVAX vaccine is designed to both destroy pre-existing cancerous tumors and prevent cancer.

NCCS also obtained a research grant to SGD $ 800,000 National Medical Research Council, Singapore to support the evaluation of the immune response induced by vaccination of the subjects of the clinical trial. Jake Frank, managing member of MicroVAX said: "MicroVAX is pleased to be in partnership with Dr Toh Han Chong and his world-class team of clinical immunologists at the National Cancer Center of Singapore Cancer and Research Institute clinical Singapore on the initial clinical test sound vaccine against cancer. "

the vaccine against the MicroVAX cancer

consists of the attachment of the target protein, MUC-1 expressed on the surface of the aforementioned cancers, the immune powerful CD40L stimulation molecule. This new combination aims to further the power of the full body's immune system to attack the protein of cancer of the surface, MUC1, killing the cancer cells themselves.

Pre-clinical testing, the results were reported in the Journal of Immunology, showed that MUC-1 vaccine / CD40L can overcome immune nonresponse states (anergy), inducing an immune memory response and induce a complete withdrawal of existing cancers that are progressing. The concept of vaccine platform was launched at Yale University and was later supported by grants from the Breast Cancer Research Foundation, the Department of Defense, and the Sidney Kimmel Foundation for Cancer Research .

In addition to the implementation of the TAA / ecdCD40L vaccine platform for multiple types of cancer, MicroVAX studied vaccine platform for application to several infectious diseases. "This trial highlights the strong partnership between an academic research organization as SCRI with a biotechnology company and MicroVAX as a prestigious institution of health care as NCCS in the conduct new clinical trials in Singapore. It is also the first time SCRI launches in sponsoring clinical trials to support the clinical trial community in Singapore, "said Dr Teoh Yee Leong, CEO, SCRI.

NTU research could lead to better treatment options for children with leukemia

NTU research could lead to better treatment options for children with leukemia -

A research team led by Nanyang Technological University (NTU) scientists made a key finding which should open better treatment options for children with leukemia.

They found that two in three cases of acute lymphoblastic leukemia, a type of cancer of white blood cells, can be caused by mutations in one of two key genes found in children. These genes, however, are more common in people with Down syndrome.

This means that scientists can design better treatment protocols, depending on the mutated gene is carried by the patient. These treatments may include lower doses of anticancer drugs thus leading to less side effects.

Acute lymphoblastic leukemia is the most common cancer in children, with 50 to 100 children diagnosed annually in Singapore. This gene discovery is good news for those with Down syndrome and 20 percent of children who do not respond well to standard therapy.

Children with Down syndrome have 20 to 50 times greater risk of developing blood cancer. They are also likely to suffer a relapse and have a higher risk of dying from side effects of the therapy.

The discovery, made by an international team led by Professor Dean Nizetic Lee Kong Chian School of Medicine, NTU, was published in the prestigious academic journal Nature Communications last week.

expert team of Prof. Nizetic in aging and Down syndrome have collaborated with researchers at Queen Mary University in London and the Universities of Geneva and Padua on this study.

"by analyzing the DNA sequence of samples at different stages of the disease patients, we identified mutations in two genes that transform normal blood cells into cancer cells," said Professor Nizetic, lead author of the study.

research team found that two genes (RAS and JAK) does mutate together, making them ideal biomarkers.

"this could benefit all children affected by the disease as clinicians would be able to offer appropriate treatment, more specific and less toxic, reducing side effects and even reducing the number of deaths related to side effects " added Professor Nizetic.

team of Prof. Nizetic at LKCMedicine focuses on Down syndrome to gain a better understanding of the state, which has many complex mysteries. In people with Down syndrome, their cells show signs of accelerated aging and damage of accumulated DNA. Paradoxically, they appear to be protected against the most common cancers of solid tissues in adulthood.

"Some people with Down syndrome may be protected against age-related diseases such as dementia, atherosclerosis and type II diabetes, despite the increased risk factors," said Professor Nizetic.

"Examine those cells with Down syndrome could not only help to lead longer and healthier lives, but also provide important clues in understanding general mechanisms of aging, Alzheimer ' Alzheimer's, cancer, atherosclerosis, diabetes, and a number of other common conditions, which so far has not been sufficiently explored. "

Moving forward, the 'NTU research team will conduct more studies on the results of two key genes. This is to see how well they could affect normal children and children with Down syndrome, who suffer from this form of leukemia.

Down Syndrome Association (Singapore) welcomed the discovery

Dr Balbir Singh, advisor and founding president of Down Syndrome Association (Singapore), hope these findings will lead to "better treatment less toxic to all children affected by this disease, "and welcomed the new interest in research in Down syndrome

" associations and organizations of parents and carers for people with Down syndrome are very interested in participating in research that could improve the prospects for improving their health, quality of life and inclusion in society, "said Dr. Singh.

"It makes people with Down syndrome twice as proud, and feel important and included if their study may help to better understand and combat diseases such as Alzheimer's disease, cerebrovascular accident, heart attack and cancer, for all people. The Down Syndrome Association (Singapore) welcomes more research in this direction. "

Assumptions about adolescent sexual activity results in vaccination rates against HPV down

Assumptions about adolescent sexual activity results in vaccination rates against HPV down

-

Probing deeper into the complex decisions that parents and providers face in regarding the human papilloma virus (HPV), researchers found that if the two sides appreciated the importance of the vaccine against HPV, personal assumptions surrounding the administration schedule relative to the start of the activity sexual resulted in a decrease in immunization rates.

medical school researchers from Boston University (BUSM) conducted hundreds of interviews offer new perspectives in this room the frequent and often controversial-clinical conversation. Their conclusions and recommendations appear in the September 2014 issue Pediatrics .

More specifically, the researchers found that immunization rates could be attributed to personal bias and communication styles suppliers. Suppliers who believed a child was at low risk of sexual activity of an evaluation, they admitted, not always accurate, were more likely to delay the administration. Often this delayed decision was never reviewed. Those with high rates of vaccination approached vaccines against HPV as part of the routine vaccine beam 11, unequivocally, he advised parents, and framed the conversation as one on cancer prevention.

"The focus on cancer prevention and coadministered with other routine childhood vaccines has the potential to greatly reduce missed opportunities occurring in many intentioned providers and relatives, "said lead author Rebecca Perkins, MD, M.Sc., assistant professor of obstetrics and gynecology at BUSM and a gynecologist at Boston Medical Center.

researchers interviewed 124 parents and 37 health care providers in four clinics between September 2012 and August 2013 were invited parents and providers to discuss their reasons for their vaccine against HPV eligible girls did or did not finally received the vaccine. Remarkably the most common reason for parents (44 percent) was that their child has never been offered the vaccine. other common reasons included the perception that vaccination was optional or recommended instead of being told by their supplier that it was useless before the first sexual intercourse. Among those who refused the vaccine, the reason often involved issues of security and the belief that their daughters were too young to need.

Dasatinib: leukemia drug promising for the treatment of the skin, breast and other cancers

Dasatinib: leukemia drug promising for the treatment of the skin, breast and other cancers -

A drug against leukemia called promising dasatinib for the treatment of the skin, breast and several other cancers, according to researchers at Loyola University Chicago Stritch School of Medicine.

dasatinib fights leukemia checking the uncontrolled growth of cancer cells. But when used against other cancer cells, the researchers found, the drug uses a different strategy: It causes the cells to clump together, preventing them from migrating. Without the ability to migrate, cancer cells may metastasize (spread to other parts of the body).

Mitchell Denning, Ph.D., and his colleagues discovered the molecular mechanism behind this cell-cell adhesion. The researchers reported their findings in a study published online ahead of print in the journal Molecular Carcinogenesis .

Dasatinib (trade name Sprycel) is approved for certain types of leukemia. It targets a protein called BCR-ABL that fuels the growth of cancer cells.

BCR-ABL is similar to a protein called Fyn which is found in other malignancies, including breast, brain, pancreas, skin and head and -neck cancers. Fyn is associated with cell-cell adhesion and cell migration.

Denning and colleagues found that the application of dasatinib cancer cells in the laboratory caused the cells to clump together and also prevented cells from migrating. They found similar results with breast cancer cells. While dasatinib has not eliminated Fyn, it inhibits the activity of the protein.

The researchers also found that dasatinib has reduced the number and size of tumors in mice that had skin cancer.

Denning noted that clinical trials are underway to test dasatinib in patients with melanoma, prostate cancer, pancreatic cancer, endometrial cancer, cancer stromal gastrointestinal, ovarian cancer, multiple myeloma, Hodgkin lymphoma, and acute lymphoblastic leukemia.

"We believe that dasatinib can be applied to many different types of cancer," said Denning.

Research shows that African Americans are heavier burden DME

Research shows that African Americans are heavier burden DME -

Search Keck Medicine of USC ophthalmology researchers shows that African Americans are heavier burden of diabetic macular edema (DME), a leading cause of blindness in diabetic patients in the United States.

research published online today in the Journal of the American Medical Association (JAMA) Ophthalmology , indicates a higher burden of diabetes IP vision loss in certain ethnic populations due care access issues, said corresponding author Rohit Varma, MD, MPH, director of the eye Institute and USC professor and chairman of ophthalmology at the Keck School of Medicine of USC.

"We were surprised that our research has shown that African-Americans have EMR rates, higher when Hispanics tend to have the highest prevalence of diabetes," said Varma, who is recognized as one of the principal investigators of eye diseases in underserved populations. "There is not enough DME vision screening in diabetics, but there are many better therapies available that are covered by insurance. We hope our research will help those in position to influence policy for better control over costs and where the need for treatment is greatest. "

diabetic eye disease is the a leading cause of vision loss in older people 20-70 years. Approximately 347 million people worldwide suffer from diabetes mellitus, and the Centers for Disease Control estimates that 25.8 million Americans had diabetes in 2010.

diabetic macular edema results when fluid and protein accumulates on the macula of the eye, which is part of the retina, which causes thickening and swell. central vision of the victim is affected and untreated, the disease can vary from slight blur to blindness.

Varma team conducted the study using the National Health and the study database Nutrition Examination (NHANES), a measure of the national dataset health and nutritional status of adults and American children. The evaluation was a survey of about 5,000 Americans each year since the early 1960s and is used by researchers nationwide to determine the prevalence of major diseases and risk factors for disease.

As part of NHANES, subjects undergo a physical examination includes photos of their retinas, which team Varma examined to determine the prevalence of DME.

Clinicians should evaluate patients with diabetes, particularly those who are African American or Hispanic, closer to vision loss, Varma advised. He also said that patients should do their utmost to control their blood sugar and monitor their own vision. Varma said that August is when we commemorate National Eye examination Month -. A perfect time for ophthalmologists and patients to focus on eye health

Varma next target for research in this area is to examine the barriers to access to eye care among African Americans.

Sen. Pryor made his debut ad campaign embracing the provisions of the health law

Sen. Pryor made his debut ad campaign embracing the provisions of the health law -

The Arkansas Democrat who is in a tough re-election fight, spoke of his own struggle with cancer and how the health law provisions that prohibit insurance companies from denying coverage to people with medical problems could have helped

the Associated Press :. 'Obamacare' announcement Pryor Highlights of his fight against cancer
US Senator Mark Pryor reached into his own medical history on Tuesday to explain his vote on the new law of the nation's health care, saying Arkansans his battle with a rare cancer 18 years ago has influenced. The two-term Democrat, who is in a difficult re-election battle, fought a clear cell sarcoma discovered after a game of basketball pickup. He had five weeks of chemotherapy and surgery for 13 hours as its called experimental campaign (8/20)

Washington Wire The Wall Street Journal :. Democratic Pryor Embraces Obama Health Care Law-In Ad
Mr. Pryor talks about his own battle with cancer and appears for the first time in a campaign ad with his father, former senator and governor David Pryor, one of the most popular state Democrats. Although the senator did not mention the Affordable Care Act by name, it boasts support for the law his father proudly mentions that his son's insurance company would not pay for treatment after being diagnosed with a form rare cancer in 1996 (Hook, 8/20)

The Hill :. Pryor touts O-Care Vote For New Ad
"When Mark was diagnosed with cancer, we thought that we could lose," said David Pryor in the ad. "Mark's insurance company would not pay for the treatment that ultimately saved my life." The young Pryor then cites ObamaCare regulations requiring insurance companies to provide coverage for preexisting conditions (Joseph, 8 . / 20)

Bloomberg / Businessweek Democrat running on Obamacare Without Mentioning Obamacare
a democratic politician fighting against the reelection is using a strategy few would have imagined it six months ago: Arkansas Senator Mark Pryor has released a new ad boasting about his yes vote for Obamacare. well, sort of. the ad never mentions the affordable care Act by name. instead, it starts with Pryor and his father talk Senator own treatment of cancer and fighting with his insurance company to get covered (Tozzi, 8/20).

---

This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a professional health policy research non-partisan organization affiliated with Kaiser Permanente.

New risk calculator can evaluate the risk of developing a psychosis of the individual

New risk calculator can evaluate the risk of developing a psychosis of the individual -

A new risk calculator can predict the risk of developing psychotic disorders such as schizophrenia of an individual, according to a new study published today in the American Journal of Psychiatry . The research involved collaborators from nine sites, including Beth Israel Deaconess Medical Center (BIDMC) and may help researchers test treatments to prevent the onset of full psychosis.

Psychosis is characterized by hallucinations and delusions. The new calculator assesses the risk of developing a psychosis after experiencing early warning signs of schizophrenia, such as hearing voices of an individual

"Until now, clinicians may give patients only a rough estimate of how their condition may progress. - What about 15 to 25 percent of people who experienced early warning symptoms will be to develop a more serious condition, "said Larry J. Seidman, PhD. D., a psychologist at BIDMC and Professor of psychology at Harvard Medical School. "With this new risk calculator, clinicians can now give patients an individual risk assessment. More specific information allows people to have a more realistic sense of what is happening, which can reduce anxiety. "

In more stressful life events, trauma and family history of . and schizophrenia, the calculator takes into account five factors to determine the risk level of an individual These factors include: age of onset, levels of unusual thought content and suspicious; social functioning; powers verbal learning. and mental processing speed

Seidman and her colleagues analyzed data from interviews with 596 subjects, aged 12 to 35 who were diagnosed with attenuated Psychosis syndrome, a condition in which patients may experience hallucinations and / or develop unusual thoughts but acknowledge their perceptions are not based in reality.

the research team, led by Tyrone Cannon of Yale University, PhD, then developed the risk calculator that analyzes risk factors for schizophrenia. After following with the subjects every six months, the researchers found that 16 percent of patients diagnosed with Attenuated Psychosis Syndrome had converted to psychosis within two years.

The symptoms of unusual thought content and suspicion have contributed most at risk of developing psychosis. A decline in social functioning, less verbal learning and slower processing speed were also important factors. People who were younger (in their teens or early twenties) when their symptoms began, also have an increased risk. Stressful life events, trauma and family history of schizophrenia found to have a lower impact on the risk profile of an individual

"The risk calculator does not account processing or other potentially favorable environmental factors that can reduce the risk. this is a direction for future research, "said Seidman, adding that the power of the computer lies in the development perspective of the symptoms for patients and their families. "Having hallucinations, he is, does not add much weight at all predictive Maybe that person has good cognitive function and has not decreased socially - .. This profile would lead to a good score of treatment can result, potentially with less fear. "

BD Announces Winners 2014 "Innovations in Care" price

BD Announces Winners 2014 "Innovations in Care" price -

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company - in partnership with Direct relief and the national Association of Community health Centres (NACHC) - announced the winners of the "Innovations in care" 2014 awards to seven community health centers as part of BD help build healthy communities ^MS initiative. the announcement was made at 2014 national Association of Community health centers (NACHC) Institute of Community health and Expo held in San Diego, CA.

BD help build healthy communities is a four-year initiative to expand access and improve care for underserved and vulnerable populations in the United States initiative, announced in 2012 with a founding commitment to the Clinton health Matters initiative, includes a BD commitment of approximately $ 5 million in cash and product to clinics and community health centers (CHCs) across the United States. The initiative has two components, including:

1. A commitment to donate at least 20 million insulin syringes and needles to community health centers across the country to support management of diabetes care for the uninsured and underinsured Americans. To date, BD has donated 9.1 million syringes to community health centers.
2. Innovation in care rewards of up to $ 100,000 to CSC that address the prevention and treatment of diseases that disproportionately affect vulnerable populations. Awards are based on proposals by CSC for innovative approaches to diabetes, cervical cancer and HIV prevention and management. BD has a long history of developing tools to help diagnose and manage these conditions and is determined to improve care for those who do not have access. The decisions on the winners of innovation are guided by a panel of examiners with expertise in clinical and community health care in all three disease areas.

The winners of the 2014 award include seven CSC, who will receive prize money of $ 100,000 to support their innovative programs:

prevention and management of diabetes
Santa Rosa Community health Center - Santa Rosa, CA
Asian health services - Oakland, CA
Utah health System Navajo - Montezuma Creek, UT
Health Cente Roanoke Chowan Community r - Ahoskie, NC

prevention and management of HIV
Morris Heights Health Center - Bronx, NY
Housing Works health services III - Brooklyn, NY

cervical cancer prevention
Charles Drew health Center - Omaha, NE

"clinics and community health centers throughout the country provide essential services to millions of uninsured Americans and underinsured. The dedicated professionals who work in these clinics are developing innovative approaches to care that meet the specific needs and circumstances of the communities they serve, "said Vincent A. Forlenza, Chairman, CEO and President of BD." We are delighted and proud to provide support to initiate and scaling of these new models of care. in the coming years, we will work with Direct relief NACHC and widely communicate the success of these programs in local centers . Community health at the national level so that they can be reproduced if necessary "

" the BD help build healthy communities initiative recognizes an enormous and generally unknown fact: clinics and community health centers are the safety net for America's health care and provide quality, affordable preventive and primary care to those who would not otherwise, "said Thomas Tighe. President and CEO of Direct Relief "Direct Relief is delighted to work again with BD on this new and unique initiative to support these providers."

community health centers serve 23 million people - one in 15 people living in the United States. people who use a health center as their home health care have lower rates of visits to emergency departments and hospital admissions. the demand for affordable primary care is expected to surge in the coming years, more people have access to insurance coverage. Yet there are still 62 million people living in America who struggle with little or no access to a primary care provider.

"This multi-year initiative brings together resources that make a difference in the lives of the medically underserved," said Malvise A. Scott, Vice President of Partnership and Resource Development at NACHC. "We appreciate this partnership and recognition of the important work of community health centers across the country. "

Innovative treatment nanobubble detects and destroys cancer cells in mice

Innovative treatment nanobubble detects and destroys cancer cells in mice -

The innovative technology developed by researchers funded by the NIH was able to find and to facilitate the killing cancer cells in mice without harming surrounding healthy tissue. A treatment using this technology in humans could reduce the cancer recurrence rate or metastasis.

The cancer cells that can not be removed by surgeons often cause tumors to metastasize or return. In a study published in Nature Nanotechnology in February, Dmitri Lapotko, Ph.D., and his team at Rice University (now with Masimo Corporation, CA) describe a new way to fight against these residual cancer cells. In this new approach, the tiny gold particles have specific cancer antibodies attached to their surface, which allow particles to be swallowed up in high concentrations and cluster only in cancer cells. These gold clusters, when exposed to a short wide laser pulse, heat and the surrounding liquid evaporation, producing a "nanobubble plasmon." This nanobubble produced a "pop sound" that reveals the cancer cell and causes an explosion that destroyed from within

The researchers examined gold nanoparticles to treat cancer in the past, but the particles were missing specificity. they were unable to differentiate between healthy cells and cancer cells. Lapotko and his team are the fight against this problem by combining the use of gold particles coated with antibodies to the nanobubbles generation created with a short laser pulse.

The gold particles can be injected prior to surgery so they can go to and gather in cancer cells. After a tumor is removed in surgery, laser (near infrared) energy pulse is weak, that can move safely through a centimeter of fabric is applied. The laser pulse does not cause the damage induced in nanobubble remaining cancer cells with gold particles and which are only destroyed. This unique approach may be able to reduce the amount of unintentional damage done to the patient, especially if the tumor is located in a sensitive area like the brain, head and neck, breast or prostate cancer.

"This is a creative and innovative approach that combines an understanding of heat transfer basic biophysics with exquisite specificity and chemistry of targeting antibodies," said Rosemarie Hunziker, director of the tissue engineering program the NIBIB. "This could become a powerful tool in our arsenal to fight against cancer."

When surgeons have injected these gold particles to mice with cancer before surgery, initial results have been impressive. While 80% of operated mice group that did not receive the treatment of gold particles died due to tumors returning within 10 days after surgery, none of the mice that received tumor regrew treatment nanobubble further in the next two months.

researchers hope to begin clinical trials in humans in the coming years.

Study: US experienced the widespread adoption of the ablation prostate surgery robot-assisted in recent years

Study: US experienced the widespread adoption of the ablation prostate surgery robot-assisted in recent years -

A new study reveals that the US experienced widespread adoption of the surgical ablation of the prostate robotic-assisted for treating prostate cancer in recent years. The BJU International study also found that although these surgeries are more expensive than traditional surgeries, their costs decrease over time.

In 01, surgeons began using robotic technologies in the operations to remove the prostate. To examine trends in the use of these robotic-assisted radical prostatectomy (RARP) procedures for patients with prostate cancer, Steven Chang, MD, MS, of Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital, led a team that analyzed 489.369 men who underwent non-RARP (ie, open or laparoscopic radical prostatectomy) or RARP in the US from 03 to 2010.

over of the study period, the adoption of RARP (defined as the execution of more than 50 percent of the annual radical prostatectomy with robotic approach) rose 0.7 percent to 42 percent of surgeons performing prostatectomies radical. Surgeons who have made at least 25 radical prostatectomies a year were more likely to adopt RARP. In addition, from 05 to 07, adoption was more common among surgeons in teaching hospitals and hospitals in intermediate and large. After 07, the adoption was more common among surgeons in urban hospitals. RARP was more expensive, contributing disproportionately to the increase of 40 percent of annual expenditures of prostate cancer surgery; However, RARP costs generally decreased and reached a plateau at just over $ 10,000 while non-RARP costs rose to nearly $ 9,000 by the end of the study.

"Our findings provide insight on not only the adoption of robotic technology, but the future surgical innovations in terms of the overall trend of the early diffusion, the costs on the potential impact of new and of competitive therapies, and the alternations in best practices such as centralization of care for higher volume suppliers, "said Dr. Chang.

UCLA researchers develop a new combination therapy to activate the immune response against glioblastoma

UCLA researchers develop a new combination therapy to activate the immune response against glioblastoma -

UCLA researchers have developed a revolutionary new combination treatment that uses a vaccine to activate a response immune against advanced brain tumors. The therapy uses an antibody blockade to prevent cancer of the brain to protect the patient's own immune cells so they can recognize the brain tumor and attack it.

The diagnosis of glioblastoma multiforme (GBM) is associated with an extremely poor prognosis in most people with the disease. median survival is estimated that follows traditional treatments, such as surgery, radiotherapy and chemotherapy, is generally 14 to 18 months.

The new results are published online in the journal JCI Insight.

The new three-year study led by Drs. Robert Prins, Linda Liau and Timothy Cloughesy, all members of UCLA Jonsson Comprehensive Cancer Center, showed for the first time a vaccine to dendritic cell, in combination with the antibody blockage of a cell surface receptor immune known as PD-1 of the name, produces a more effective response immune response against GBM beyond the use of either treatment alone.

"These results are the first to accurately describe the mechanism by which an effective immune response can be seen in tumors in the brain," said Prins, an associate professor in the Department of Neurosurgery at UCLA . "We found that the effective anti-tumor immunity for glioblastoma must have a significant infiltration of killer T cells and blockaded major checkpoint axes that make these killer T dysfunctional cells within the tumor."

Prins and his team added that the combined treatment is effective to remind the immune system that the WBG is a foreign invader, which essentially prevents brain cancer to recur or more.

administration PD1 / PD-L1 antibody blockade alone may not be successful in glioblastomas that do not have a significant infiltration of T cell vaccination of dendritic cells allows the infiltration of cells in brain tumors T, while the PD-1 (mAb) antibody blockade removes the shield of active tumor to hide from the immune system.

The methodology differs from previous research in metastatic melanoma cancer and non-small cell lung cancer because it shows that activation of an immune response using vaccination of dendritic cells may be necessary in tumors that do not respond to / PD-L1 checkpoint inhibitors only one PD.

the next step of the research is to understand how the signaling mechanism of the PD-1 pathway / PDL1 integrated into other potential means of immune suppression are currently being investigated.

Study: Many HIV-infected African Americans can receive effective doses of maraviroc medicines

Study: Many HIV-infected African Americans can receive effective doses of maraviroc medicines -

Many African Americans may not receive effective doses of the drug maraviroc HIV, a new Johns Hopkins study suggests. Initial dosing studies, completed before the drug was approved in 07, included most European Americans, who generally lack a protein that is key to remove the body maraviroc. The current study shows that people with the maximum levels of the protein - almost half of African Americans - are left with less maraviroc in their bodies compared with those lacking protein, even when given the same dose. A simple genetic test for the gene that makes the protein CYP3A5 could be used to determine the doses would achieve effective levels in individuals, the researchers say.

The results of the small study were published online Aug. 12 in the journal Drug Metabolism and Disposition .

"Because African Americans are disproportionately affected by HIV infection, it is doubly important that we have the right dosage," said Namandje Bumpus, Ph.D., Assistant professor of pharmacology and molecular sciences at the medical school at Johns Hopkins University.

CYP3A5 is a protein that is abundant in the liver and intestinal cells. it adds an oxygen molecule various drugs to make them more soluble in water, so they can get in the end of the urine and leave the body. Eighty to 0 percent of European Americans not CYP3A5, because they have inherited two copies of the CYP3A5 gene dysfunctional

Normally, the absence of CYP3A5 is not noticeable. a very similar protein, CYP3A4, acts on most of the same drugs. However, for some drugs as maraviroc and drug vincristine against cancer, CYP3A5 appears to play a particularly important role in helping to remove the body. In these cases, the presence or absence of CYP3A5 would probably affect the amount of drug in the blood, the Johns Hopkins team predicted. And since 85 percent of participants in the study of maraviroc dosage were European Americans, who generally lack functional CYP3A5, researchers have hypothesized that the recommended dose for maraviroc could be too low for those two functional copies of the gene - which 45 percent of Africa -Americans

to test this idea, the research team gathered 24 healthy volunteers according to the number of functional copies of the CYP3A5 gene they had -. zero, one or two. They each received a single dose of maraviroc in the recommended dose of 300 milligrams, and the blood of each participant was taken at 10 time points over 32 hours.

In almost all time points, maraviroc concentrations were similar for the groups with zero or one functioning copies of CYP3A5, but were lower in those with two copies of operation. Compared to those two malfunctioning gene copies, those with two copies running had a concentration of 41 percent lower overall. It is important, as a group, those with two functional copies had an average concentration which was just above the lowest level determined to be effective against the virus. And four of eight had average concentrations of individual who dropped below.

"The trend that we saw was that the most functional CYP3A5 a person had, the faster maraviroc was treated and left the body, the higher its concentration in the blood," says Bumpus. "What is is that if a larger study confirms that we are under-dosing of this group, a simple genetic test before dosing decisions could remedy the situation. "

She adds that this study shows highlight the importance of clinical trial design in which participants are as ethnically diverse as the population to be treated.

Scientists reveal how common asymptomatic condition can develop in the myeloma

Scientists reveal how common asymptomatic condition can develop in the myeloma -

Researchers from Birmingham University and hospitals across the West Midlands revealed how a condition asymptomatic town can develop myeloma blood cancer.

They found that changes in the bone marrow needed for the cancer to grow have already taken root in the previous condition, raising the possibility that early medical intervention could prevent this type of incurable cancer to take root.

research, which was funded by the blood cancer charity Bloodwise, is published today in the journal leukemia .

Myeloma affects the plasma cells, a type of white blood cell that originates in the bone marrow. Diagnosed in more than 4,000 people a year in the UK, less than half of patients survive more than five years after diagnosis. Symptoms often include debilitating and painful bone damage, anemia and nausea

Myeloma almost always progresses in a seemingly benign condition called "MGUS", which is especially common in the elderly -. As much as 7% of people aged over 85 have MGUS. Only about one in 100 patients with MGUS develop myeloma each year and there is currently no way to accurately predict which patients do and when.

Myeloma will spread to other organs, suggesting that the myeloma cells depend on the support of other cells in the bone marrow environment to survive. The researchers showed that Birmingham early in the development of MGUS, the cells that make up the connective tissue of the bone marrow change their behavior and become more favorable to the growth of cancer. They discovered that a key gene, called "PADI2" becomes particularly overactive in these connective tissue cells, which leads to overproduction of a signaling molecule known as interleukin-6 (IL-6).

conjunctiva release of IL -6 cells in the bone marrow, where it binds to receptors on the surface of malignant plasma cells, asking them to multiply rapidly and to resist cell death signals . It is already known that the presence of elevated levels of IL-6 in bone marrow of the patient significantly reduces the effectiveness of a key chemotherapy drug called bortezomib.

The researchers believe that drugs designed to target the gene PADI2 in MGUS and myeloma patients can significantly reduce the support signaling that myeloma cells are dependent, and can increase the effectiveness of current treatments.

significantly the PADI2 gene has also been linked to the development of other types of cancer, rheumatoid arthritis, Alzheimer's disease and autoimmune disease, and any drug developed could have wider applications beyond myeloma

Dr. Daniel Tennant, who led the research at the University of Birmingham, said :. "It is now clear that the bone marrow of patients with MGUS, traditionally considered a benign condition, is significantly different from that of healthy individuals. Environmental bone marrow in these patients seems to be able to support the growth of cancer even though the majority of patients will not progress to myeloma.. While this research is in the early stages, it offers the exciting possibility that early intervention could delay or even prevent the development of cancer "

Dr Alasdair Rankin, director of research at the blood cancer charity Bloodwise, said: "There is an urgent need for new treatments for myeloma, which, while largely incurable, can have a devastating impact on quality of life. with a population over more, MGUS and myeloma will only become more frequent. drugs designed to eliminate the myeloma support system used to develop could be an effective way to treat the disease, or even prevent completely. "

CNIO study shows pro-inflammatory molecule IL-17A can be a key factor in the development of NASH and HCC

CNIO study shows pro-inflammatory molecule IL-17A can be a key factor in the development of NASH and HCC -

NASH (NASH) is a serious liver conditions above hepatocellular carcinoma (HCC) and is currently incurable. A study in search of the Spanish National Cancer Centre (CNIO) shows that a pro-inflammatory molecule IL-17A, is a key factor in the development of this pathology, and stresses that blocking IL-17A or inhibiting cells that secrete IL-17A with drugs such as digoxin (antiarrhythmic agent) may be useful for preventing NASH in patients predisposed to develop HCC.

HCC is the most aggressive liver tumor and a major cause of morbidity in cancer. Several risk factors have been associated with this cancer and its early stages, but the molecular mechanisms underlying the carcinogenic process remain unclear.

non-alcoholic fatty liver disease (NAFLD), characterized by the accumulation of excessive fat, is prevalent among obese people, patients or people infected with the virus-diabetes, and it is a important risk factor for HCC development. However, all obese people are changing at the most severe form NASH, which has a significant inflammatory component.

"The fat accumulation (steatosis) by itself can not explain the occurrence of NASH. In contrast, inflammation determines the progress and results of the disease, since only 10% 20% of obese patients with fatty liver disease will eventually develop NASH, "said Nabil Djouder, leader of the study. That Djouder and colleagues found that NASH, which is currently incurable, is the result of several "hits" and that "the first step is DNA damage to promote inflammation caused by excess nutrients" .

working with different mouse models, the authors demonstrate in the latest issue of Cancer Cell how excess nutrients stimulate the expression of an oncogene called URI in the liver. URI -which is also upregulated in viral hepatitis- leads to DNA damage in hepatocytes, which triggers systemic inflammation and crosstalk between white adipose tissue and the liver that ends ultimately in NASH.

Where DNA damage occurs in hepatocytes, immune cells infiltrate the liver, especially Th17 cells which release pro-inflammatory molecule IL-17A. This molecule, which is a cytokine induced neutrophil infiltration of adipose tissue which leads to insulin and the release of fatty acids resistance, resulting in non-alcoholic steatohepatitis. "Type 2 diabetes seems to precede NASH and HCC," said Djouder.

The researchers also treated healthy mice with injections of IL-17A and observed how the first signs of NASH appeared after four weeks, which confirms its crucial role in the development of the disease . Moreover, Djouder and his team blocked IL-17A using various methods -antibodies and digoxin among others- and prevented the development of NASH and HCC.

In addition, the URI of expression and IL-17A were positively associated with nonalcoholic stetatohepatitis and HCC in obese, HVB and HCV patients. This finding should pave the way for a new prevention strategy for NASH and HCC in high-risk patients, particularly diabetes or infection with viral hepatitis.

"HCV treatment is a socio-economic challenge of our society that blocking IL-17A [...] with digoxin may provide a cheap and effective prophylaxis for hepatitis B and C infected patients with high risk for NASH and HCC, "concludes the newspaper.

Researchers at Yale University identified the bacterial culprits that lead ITN

Researchers at Yale University identified the bacterial culprits that lead ITN -

Yale University researchers have identified a handful of bacterial culprits that can lead inflammatory diseases of the intestine (IBD) such as Crohn's disease and ulcerative colitis, using the own intestinal immune responses of patients as a guide.

results are published Aug. 28 in the journal cell .

trillions of bacteria exist in the human intestinal microbiota, which plays a crucial role in the development and progression of IBD. However, he thought that only a small number of bacterial species affect the susceptibility of a person to the EIA and its potential severity.

"A handful of bad bacteria are able to achieve access to the immune system and get right in the gut," said Richard Flavell, Sterling Professor of Immunobiology at Yale School of Medicine. "If you look at the bacteria we did an immune response, you can begin to find these bad actors."

Flavell research team focused on antibodies coatings on the surface of bacteria. In particular, Yale researchers examined bacteria with high levels of an antibody called immunoglobulin coating A (IgA).

"The coating is the attempt of the body to neutralize the bacteria," said Flavell. "It binds to bad bacteria. We make these IgA responses to a limited number of organizations. "

He and his team have confirmed a correlation between high levels of IgA coating and inflammatory responses in the human gut. To do this the team collected the "good" and "bad" bacteria from a small group of patients and transplant them into mice. in healthy mice, there was no influence on the intestinal inflammation. in mice with induced colitis, those with the bacteria suspected of "bad" showed signs of excessive inflammation and other symptoms of IBD

Flavell warned that more research is necessary to learn how many bacterial species are classified "bad" and if these populations are common to all patients with IBD or are unique to each patient.

But the study results indicate that the anti-bacterial therapies for IBD are possible, Flavell said. Such anti-bacterial approaches may include very specific antibiotics, vaccines and probiotics.

"We believe an antibacterial strategy has a place in the treatment of IBD," said Flavell.

Scientists discover new and unexpected features of collagen

Scientists discover new and unexpected features of collagen -

WHAT: Scientists from the National Institutes of Health show unexpected new details about the fundamental structure of collagen, the most abundant protein in the human body. In laboratory experiments, they showed that collagen once considered inert forms structures that regulate how certain enzymes decompose and reshape the body tissues. The discovery of this regulatory system provides a molecular view of the potential role of physical forces at work in heart disease, cancer, arthritis, and other processes related to the disease, they say. The study appears in the current online issue of Proceedings of the National Academy of Sciences .

Scientists have known for years that collagen remodeling plays an important role in a variety of biological processes ranging from wound healing to cancer growth. In particular, researchers know that collagen is broken down by a certain class of enzymes called matrix metalloproteinases (MMPs), but exactly how they did it remained somewhat of a mystery, until now.

In the NIH study, the scientists isolated individual, collagen fibrils of nanoscale rat tail tendons. They then exposed the fluorescence labeled collagen fibrils human MMP enzymes. Using video microscopy, scientists have followed thousands of enzymes that move along a fibril. Unexpectedly, the scientists observed that the enzymes have preferred to fix in some places along the fibrils, and over time these binding sites moved slowly, or disappeared and reappeared in other positions. These observations revealed collagen fibrils have defects that form spontaneously and heal. In the presence of voltage, such as tendons stretching, defects are probably eliminated, which prevents collagen decomposition enzyme which is responsible for the physical strength, the researchers suggest. In short, they have identified a possible mechanism of the sensitive strain to regulate tissue remodeling.

Research Roundup: Benefits of hip surgery; prevention of surgical infections; assess the predecessors of OCA

Research Roundup: Benefits of hip surgery; prevention of surgical infections; assess the predecessors of OCA -

Each week, KHN compiles a selection of studies and health policy briefs published recently

Clinical Orthopaedics and related research :. Surgery For Hip fracture yields benefits to society beyond the direct medical costs
Surgical treatment of hip fractures can achieve better survival and functional outcomes than non-surgical treatment, but less is known about its economic benefits. ... We felt the effects of surgical treatment of hip fractures displaced through a cohort of Markov analysis of patients 65 years and older. ... Average life social benefits estimated per patient exceeded the direct medical costs of hip fracture surgery by $ 65,000 to $ 68,000 for displaced fractures of the hip. Except for the management of nursing household care, sensitivity analyzes show that surgery produces positive net social savings (Gu, Koenig, Mather and tongue, 8/5)

JAMA Surgery :. Preventive surgical site infections Bundle In colorectal surgery
surgical site infections (ISO) are associated with increased morbidity, length of hospital stay, readmission rates and costs of health care. They represent a particularly important issue in colorectal surgery, for which SSI rates are abnormally high, ranging from 15% to 30%. ... To a large extent, up to the point [of reducing SSIs] has been on improving adherence to evidence-based practices ... The SSI preventive [systemic, evidence-based measures called] beam has been associated with a substantial reduction of SSIs after colorectal surgery. The increase in costs of supporting SSIs that the beam is an effective approach to reducing the costs of health care (Keenan et al, 8/27.)

Medicare and Medicaid review of research :. financial impact and quality of the Medicare physician group practice demonstration of
[The health law's Accountable Care Organization program] was built directly on its predecessor, the Medicare Physician Group Practice (PGP) Demonstration .... This paper presents the results of the overall evaluation funded by CMS PGP demonstration ... all ... the impact was a saving of $ 171 per year attributed person beneficiary during the demonstration performance period .... This represents a saving of 2.0 per cent of expenditure affected beneficiaries. CMS has paid performance bonuses to PGPs participants on average $ 102 per year assigned beneficiary within five years of demonstration

Medical Care (Pope et al, 8/28.). The intended and unintended consequences of the quality improvement interventions for small practices in a community project Electronic Health Record implementation
despite the rapid increase in the implementation of electronic health records (EHRs) , commensurate improvements in the quality of health care is not always respected. ... The study included 143 practices implemented EHR .... 71 practices were randomized to receive financial incentives and quality assessments and 72 were randomized to one feedback. ... The incentives- technical and financial assistance, alongside implementation- EHR can improve the quality of care. Financial incentives for quality may not result in similar improvements for measurements and incentives unincentivized (Ryan et al., 8/27).

Infection Control and Hospital Epidemiology / Rand Corp. Association of State legal mandates for Central submitting data related to intravascular catheters infections in neonatal intensive care units with the process and outcome measures
[This cross sectional study was designed] to determine the association between the state legal mandates for the presentation of the central line infections associated with blood circulation (CLABSIs) in neonatal intensive care units (NICU) with process measures and results. ... Of the 10 NICU study, 107 (56.3%) were located in states with mandates, mandates up> 3 years in 52 (49%). ... Mandates were predictors of compliance with all practices ≥95% of

This is a selection of news coverage of other recent research (Zachariah et al, 8/22.) :.

MedPage Today: Surgery No Help for Mild osteoarthritis
arthroscopic surgery for degenerative meniscal tears in patients with osteoarthritis of the knee slightly was no benefit for the function or pain, a meta-analysis determined. In randomized trials included 805 patients, the standardized mean difference for the function at 6 months was 0.25, which was converted to a knee injury and Osteoarthritis Outcome Score of 5.6. It has not reached the minimum important difference of 10 (Walsh, 8/27)

Fox News :. Teens With Depression Benefit From 'Collaborative Care
For adolescents with depression, find and stick with a treatment strategy can be an uphill battle. Their families often struggle to find a professional who can treat depression in adolescents, is accepting new patients and is covered by their insurance. ... But an idea called "collaborative care" -; increasing the communication between families and doctors -; can help fill this gap, said [Dr. Laura Richardson, a professor of pediatrics at Seattle Children's Hospital and the University of Washington in Seattle], who co-authored a new study detailing the findings, published today (26 August) in the journal JAMA (Geggel, 8/26)

MinnPost :. Study Links Early-To-Midlife obesity to increased risk of dementia
people who are obese in their early adulthood to midlife years have an increased risk of developing dementia, and the risk is especially high for people who are obese in their 30s, according to a study [last] week. The study also found that people who become obese later in life have a lower risk of developing dementia, particularly Alzheimer's disease (Perry, 8/22)

Reuters :. More parents think their overweight children is "About Right '
Between 1988 and 2010, the number of parents who could correctly identify their children are overweight or obese has fallen, according to a new study. ... In 1988-1994 data set, 78 percent of parents of overweight boys and 61 percent of parents of an overweight girl, identified the child as "about the right weight." This number rose to 83 percent for boys and 78 percent for girls in the 05-2010 period (Doyle, 8/26)

Reuters :. Medicaid payouts for office visits may influence cancer screening: study
in states where Medicaid pays doctors higher fees for office visits, Medicaid beneficiaries are more likely to undergo breast cancer screening, cervical or colorectal neck, according to a new study. "States tend to vary their reimbursement rates for different types of medical care, some states may have lower reimbursement for certain services and higher reimbursements for others," said lead author Dr. Michael T. Halpern health services Division and social policy research at RTI International (Doyle, 8/26)

Medscape :. Delays futile treatment Care For Others Waiting For ICU beds
patients in intensive care units (ICU) receiving a delayed unnecessary treatment or treatment of ICU prevented others who need intensive care, a study published in the September issue of Critical Care Medicine found (Laidman, 8/28).

---

This article has been reprinted kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a professional health policy research non-partisan organization affiliated with Kaiser Permanente.

BioLegend acquires shares of Covance Antibody Services

BioLegend acquires shares of Covance Antibody Services -

BioLegend, Inc. (BioLegend) acquired the shares of Covance Antibody Services Inc., a business unit of Covance located in Dedham, Massachusetts, on August 29 2014. the business unit Covance antibody develops and manufactures antibodies and research reagents for neuroscience, immunopathology, cell biology, Epitope Tag detection and immunohistochemistry. These products, including in vitro diagnostic (IVD) for IHC antibodies are well suited to complement and enhance the current selection of BioLegend research reagents. Covance antibodies can customers expect the same support and superior customer exceptional value with these products than existing BioLegend customers.

"We are delighted to add people and antibody products at Covance BioLegend team," said Gene Lay, President and CEO, BioLegend. As neuroinflammation and neurodegeneration become subjects of increasingly important, Covance antibody is an ideal strategic fit in BioLegend's commitment to promoting the discovery in neuroscience. with the addition of a world-class R & D team and more than 0 antibody products for emerging and important target countries in this area, BioLegend is positioned to become a leader in research in neuroscience and immunology.

"the addition of neuroscience and IHC antibody tools accelerated discovery means our catalog for our current and new customers. We hope to bring our quality, support and value well known in the immunology community neuroscience researchers worldwide, "said Gene Lay.

medical journalist describes slow journey to healing traumatic brain injuries

medical journalist describes slow journey to healing traumatic brain injuries -

There

Eleven years in the New England Journal of Medicine, medical journalist Susan Okie, MD, introduced the two readers veterans of the US military who have suffered traumatic brain injuries in Iraq and the challenges they face in the recovery period after return. In the July 14 issue of the NEJM, Okie describes its follow-up interviews with the soldiers, and the slow journey to recovery that continues more than a decade later.

"A visit with [Jason] and Pepper [David] ... Emme. I observed many healing evidence, not only in the way they sound and what they are able to do, but in how they seem to have feelings and dreams, "Okie wrote in the NEJM article medicine and society," long-term Monitoring of TBI. - slow progress in science and recovery "

Okie details the personal journeys of each man through the years and when they did not have health care. It explores how each symptom encountered so often associated with TBI and PTSD: insomnia and nightmares, irritability, depression, guilt and anxiety

The recovery of each man is "slow "- Pepper only received comprehensive TBI evaluation VA. hospital this year - but both continue to make progress, Okie said, and she attributes the resilience of the two men to a common factor

"Although the surgical and medical treatment was crucial to Emme and pepper to departure , close personal relationships have suffered. them during the last decade, "she wrote.

Okie observed that Emme survived a critical distance probably because a longtime friend reached out for him just in time. and she said to Pepper, it seems that marriage and devotion to the family "helped to survive periods of sorrow for what he had lost."

"in men, courage, proud to have served in the military, and loyalty to their comrades were other sources of strength, "she said.

Study shows how autophagy dietary restriction impacts in the intestine to increase the life

Study shows how autophagy dietary restriction impacts in the intestine to increase the life -

Food restriction or restricted food intake without malnutrition has beneficial effects on the longevity of many species, including humans. A new study from the Institute for Medical Discovery Sanford Burnham Prebys (SBP), published today in the journal PLoS Genetics, represents a major advance in the understanding of how dietary restriction leads to these benefits.

"In this study, we used the small roundworm C. elegans as a model to show that autophagy in the intestine is essential for extending the life span," said Malene Hansen, Ph.D., associate professor in the development, the aging of the SBP and the regeneration program and lead author of the study. "We found that intestinal worms restricted food has a higher than normal rate of autophagy, which seems to improve fitness in many ways maintaining intestinal integrity and maintaining the animal's ability to move. "

autophagy, or cell cycling, is known to play a role in extending lifespan. Autophagy involves breaking down its parts-cell decision protein, electricity production and transport systems-small molecule. This time eliminates unnecessary or broken cell machinery and provides building blocks to manufacture new components of the cell, which is especially important when the raw materials are not provided by food.

In this study, the research team wanted to understand how dietary restriction autophagy impacts in the intestine, whose proper function is already known to be important for long life.

"to the strain we used, called eat-2 is genetically predisposed to eat less, and they live longer than normal worms, so they provide an ideal model for studying how the supply restriction extends life span, "said Sara Gelino, Ph.D., research associate in the laboratory of Hansen and lead author of the study." We found that blocking autophagy in their intestines considerably shortened their lifespan, demonstrating that autophagy in this body is the key to longevity.

"These results have led us to consider how to inhibit the effects of autophagy function of the intestine . We found that the barriers of the intestine of normal to become leaky as they age, those eating-2 to remain intact. Prevent autophagy eliminated this benefit, which indicates that a non-leaky gut is an important factor for long life. "

" How gut integrity concerns longevity are not clearly understood, "Hansen commented." It is possible that the decline of the gut barrier function associated with normal aging may leave harmful substances or pathogens into the body. "

The research team also found that the deactivation of autophagy in the intestine makes the slow-eating worms long-term move around less.

" decreased physical activity indicates that autophagy in an organ can have a major impact on other organs, in this case probably muscle or neural engine, "said Hansen." Finding the link between mobility and autophagy in the intestine will require further research, but we speculate that inhibition of autophagy in the gut can affect the ability of the intestine to absorb nutrients and secrete hormones important for the function of other organs. "

Although these results suggest that increased autophagy in the intestine is generally beneficial, Hansen warns that further research is needed:" Before we can consider regulating autophagy to manage the disease, we need to learn much more about how the process works in both a single cell and the whole organism. "

many of these future studies will also use C. elegans. "Even though the worms are much simpler than humans, many of the same basic mechanisms driving their biology. The knowledge we gain from this fast research could eventually help develop new treatments that help people live longer, healthier, "added Hansen.

HICCC receives $ 18 million grant from National Institute of Cancer

HICCC receives $ 18 million grant from National Institute of Cancer -

outstanding basic research, a growing interest in translating discoveries into treatments, and a commitment to patients won the Herbert Irving Comprehensive cancer Center (HICCC) of Columbia University Medical Center (CMTC) and NewYork-Presbyterian Hospital $ 18 million over five years cancer Center National cancer Institute support grant (NCI). The grant renews the status of the center as one of only two NCI-designated Cancer Centers complete in New York and one of only three in the state of New York.

"Both clinical and research programs at the Herbert Irving Comprehensive Cancer Center have increased significantly in recent years, under the direction of Dr. Stephen Emerson, and this grant recognizes our potential to change the way cancer is diagnosed, treated and prevented, "said Lee Goldman, MD, MPH, Harold and Margaret Hatch University professor and dean of the faculties of health sciences and medicine at CMTC. "This renewal will ensure the continuity of our current research, patient care, and educational programs as we continue to add cancer researchers and clinicians at our extremely talented and dedicated team."

"the Herbert Irving Comprehensive cancer Center reflects our commitment to be a leader in the prevention, diagnosis and treatment of cancer," said Steven J. Corwin, MD, CEO of NewYork-Presbyterian Hospital. "There is still work to do, and NCI funding helps provide our physicians, nurses and staff resources to deliver the highest quality, safest and most patient-centered care. With this renewal of the grant, NewYork-Presbyterian, working with our doctors and Columbia University Medical Center, will be able to fulfill our commitment to transforming the full spectrum of cancer care to better serve patients and families facing a diagnosis of cancer. "

recent growth of HICCC included the recruitment of a number of prominent physicians and researchers (40 set during the last period of NCI funding), including the center's director, Stephen G. Emerson, MD, PhD, who joined in 2012 in its assessment, the NCI congratulated Dr. Emerson's leadership, noting that the cancer center is on a trajectory to achieve exemplary results under his leadership.

"We are delighted to be recognized once again as an outstanding Comprehensive Cancer Center by the National Cancer Institute." Said Dr. Emerson, the '56 Clyde and Helen Wu Professor of Immunology and professor of microbiology and immunology. "The national review team assessed the HICCC as exceptional or outstanding in almost all areas. This distinction recognizes and endorses the work of thousands of scientists, clinicians, educators and administrators in the fight against cancer."

Associate Director Gary Schwartz, MD, joined the center earlier this year as chief of hematology / oncology and was spearheading the expansion of clinical research and patient care . Dr. Schwartz, who came to Memorial Sloan Kettering Cancer Center (MSKCC), followed by a team of five experts from blood cancer led by Joseph Jurcic, MD, MSKCC who left to join NewYork-Presbyterian / Columbia in 2013. in 2012, Suzanne Lentzsch, MD, joined the medical center as director of the multiple myeloma and amyloidosis service Mapara Markus, MD, PhD, joined to lead the growth of blood medical center and marrow transplant program. Andrew Kung, MD, PhD, developer of the new processing center for Translational Therapeutics, joined in 2012 as Chief of Pediatric Hematology / Oncology. In 2011 Andrew Lassman, MD, became head of the neuro-oncology and medical director of clinical Office protocol data management center cancer. The main recruits such as these were made possible in part by a gift of $ 40 million in 2012 Herbert and Florence Irving benefactors and previous National Institutes of Health (NIH) and NCI grants.

The HICCC has over 250 members from Columbia six schools, 12 basic facilities and eight research programs. The Cancer Center investigators currently hold more than $ 0 million in NIH and NCI research grants. The productivity of its programs is reflected in the 3000 research and publications written by its members over the last NCI funding cycle. Some 33 percent of these papers are co-authored by researchers in the various programs and laboratories, demonstrating a strong culture of teamwork cancer center and interdisciplinary thinking

Among the Recent success of the research center are :. The work of the regulatory Cancer Networks Program, led by Jan Kitajewski, PhD, and Andrea Califano, Dr., to map genes that work together to drive aggressive forms of cancer; investigations of Breast Cancer Program, led by Dawn Hershman, MD, to characterize the short and long term risks associated with the treatment of breast cancer standard; Search multidisciplinary neuro-oncology team, led by Jeffrey Bruce, MD, of the brain-tumor systems biology, genetics, cell biology, and therapy; and the extensive work of collaboration between clinicians and basic scientists to identify drug targets for leukemia

The new patient care facilities include Irving Radiation Oncology Center, which opened in September 2013 . infusion centers both at NewYork-Presbyterian campus / Columbia in Washington Heights and Midtown ColumbiaDoctors at 51 W. 51st St. Irving and the bone marrow transplant unit in hospital, which opened in April 2014. HICCC doctors diagnosed and treated more than 3,500 new cases of cancer last year. The center offers cancer patients with access to some 0 ongoing clinical trials.

Charles B. Rangel, US Representative for the 13th Congressional District of New York, said: "I welcome the recent announcement of the National Cancer Institute that HICCC receive a grant of $ 18 million over the next five years. This significant investment reflects the commitment of HICCC find a cure for cancer and to provide outstanding patient care. I especially want to thank the medical team and dedicated support staff to put these HICCC a difference in the lives of people affected by cancer. "

Scientists are developing a new vaccine to stimulate innate and specific adaptive response

Scientists are developing a new vaccine to stimulate innate and specific adaptive response -

Although a variety of strategies based on immunotherapy are used against cancer, they are often hampered by the inability of the immune response to the tumor microenvironment enter immunosuppressive and to mount an effective response to cancer cells. Now, scientists at the RIKEN Center for Integrative Medical Sciences have developed a new vaccine that involves injecting cells that have been modified so that they can stimulate both innate immune response and the more specific adaptive response, which allows the body to keep memories and attacks tumor cells news they form. In the study published in Cancer Research , they found that the vaccine allowed the CD8 + T cell killers - major players in the immune response against cancer - to enter the tumor microenvironment and to target cancer cells.

According to Shin-ichiro Fujii, head of Immunotherapy Laboratory, who led the study, "the cancer cells have different sensitivities to the innate or adaptive response, so it is important to target both for eradicate it. We have developed a special kind of modified cell, called LUAC, we found can. "

LUAC the cells are taken from his own body of the subject, but are foreign cells. The cells are modified by the addition of a cell ligand natural killer T, which allows them to stimulate natural killer T cells with an antigen associated with cancer. The group found that when these cells are activated, in turn, promote the maturation of dendritic cells, which act as coordinators of the innate and adaptive response. The dendritic cells are essential because they allow the activation of immune memory, where the body remembers and responds to a threat even years later.

To find if she worked in real organizations, they conducted experiments on mice with an aggressive form of melanoma that also expresses a model antigen called OVA. Tests in mice have shown, moreover, that aggressive tumors could be shrunken by vaccinating animals with LUAC cells that have been programmed to display the OVA antigen. After treatment, the tumors in the treated animals were smaller and necrotic inside -. A sign that the tumor was attacked by CD8 killer + T-Cells

Fujii continues, "We have been interesting to find a mechanism, and were able to understand that LUAC treatment led to development of blood vessels in tumors that express a pair of major adhesion molecules, ICAM-1 and VCAM-1, which are not normally expressed in tumors. This allowed the killer CD8 + T cells to penetrate into the tumor. "

They also found that in animals who had undergone the treatment, cancer cells injected even a year later, have been eliminated." This indicates, "said Fujii," we have managed to create . immune memory that remembers the tumor and even later attack "

for the future, Fujii said," Our therapy is promising because LUAC typical immunotherapies should be tailor-made with clean patient cells. in our case, we use foreign cells, so they can be manufactured with stable quality. Because we found that our treatment can lead to the maturation of dendritic cells, immunotherapy may move a local treatment to a systemic treatment based on immune memory. "

Triple therapy for glioblastoma has prolonged the survival of mice with a brain cancer

Triple therapy for glioblastoma has prolonged the survival of mice with a brain cancer -

A triple therapy for glioblastoma, including two types of immunotherapy and radiation targeted, significantly prolonged the survival of mice with these brain cancer, according to a new report by scientists at the Kimmel Cancer Center at Johns Hopkins.

mouse with implanted derived mouse glioblastoma cells lived an average of 67 days after triple therapy, compared to mice lasted 24 days they received only two immunotherapies. Half of the mice that received the triple therapy lived 100 days or more and were protected against new tumors when new cancer cells were re-injected under the skin of animals.

The combined treatment described in July 11 number PLOS One is a highly targeted radiation specifically to the tumor and strategies that raise the brakes and activate the immune system of the body, for anti-cancer drugs to attack the tumor. One of immunotherapies is an antibody that binds to and blocks an immune checkpoint molecule on T cells called CTLA-4, allowing T cells to infiltrate and fight against tumor cells. The second immunotherapy, known under the name 4-1BB, provides a positive "go" signal T. stimulating anti-tumor cells

None of the treatments are new, but have been used by the Johns Hopkins team to demonstrate the value of the combination of treatments that enhance the immune response against glioblastoma, the most common brain tumors in adult man. The prognosis is generally poor, even with early treatment.

"We try to find an optimal balance between push and pull the immune system to kill the cancer," said Charles Drake, MD, Ph.D., associate professor of oncology, immunology and urology and medical oncologist at Johns Hopkins Kimmel cancer Center.

researchers believe that when the radiation destroys tumor cells, dead tumor cells may release proteins that help immune cells train to recognize and attack the cancer, said Michael Lim, MD, associate professor of neurosurgery, oncology at the medical school at Johns Hopkins University and a member of the Johns Hopkins Institute NanoBiotechnology.

"Traditionally, radiation is used as a permanent treatment to kill cancer cells directly," said Lim, who is also director of the Immunotherapy Program brain tumors and director of the Brain Metastatic Tumor Center at Johns Hopkins Medicine University. "But in this situation, we use radiation as a kind of small wood, to try to induce an immune response."

Lim said if other studies confirm the value triple therapy in animals and humans, radiation could be delivered a few days before or after immunotherapies and still get the same results. Lim said this flexibility "could make requests of this therapy among potential patients. "

the researchers say they were also encouraged to see that triple therapy created" immune memory "in mice that survived the long term. When the brain tumor cells were reintroduced under the skin of animals, their immune system appeared to protect against the development of new brain tumor.

Drake said, because the immune system generally does not generate memory (tumor) when foreign cells are still present in the body. "But the idea that this combination therapy was able to generate an immunological memory really suggest that we could make the patients and generate long-term answers."

Researchers develop a variety of clinical trials to test combination therapies against brain tumors.

Study shows how pasta consumption is associated with a reduced likelihood of general, abdominal obesity

Study shows how pasta consumption is associated with a reduced likelihood of general, abdominal obesity -

In recent years, pasta has earned a bad reputation he fatten you. This led many people to limit consumption, often in the context of aggressiveness "do it yourself" regimes. Now a study by the Department of Epidemiology, I.R.C.C.S. Neuromed in Pozzilli, Italy, does justice to this fundamental element of the Mediterranean diet, showing how the consumption of pasta is actually associated with a reduced risk of overall and abdominal obesity.

The research, published in the journal nutrition and diabetes , examined more than 23,000 people enrolled in two large epidemiological studies: Moli-sani and INHES (Italian Nutrition & Health Survey) conducted by the same department. "By analyzing the anthropometric data of the participants and their eating habits - explains George Pounis, first author of the paper - we saw that pasta consumption, contrary to what many believe, are not associated with increased body weight, quite the contrary. Our data show that enjoying the pasta according to the needs of individuals contributes to a healthy body mass index, lower waist circumference and waist-hip ratio better. "

many already demonstrated how Mediterranean diet study is one of the healthiest nutritional diet, even when we talk about weight control. Very little, however, was known about the specific role of a basic component such as pasta. Data from the study Neuromed now fill this gap

"In popular views -. Said Licia Iacoviello, head of molecular laboratory and nutritional epidemiology at Neuromed Institute - pasta is often considered not enough when you want lose weight. and some people completely prohibit their meals. in light of this research, we can say that this is not a correct attitude. We're talking about a fundamental component of Italian Mediterranean tradition, and it does there is no reason to do without it. the message from this study, as other scientific analyzes conducted in the Moli-sani project and INHES, is that the Mediterranean diet, eaten in moderation and respecting the diversity of all its elements (first pasta), is good for your health. "

American Journal of Public Health special issue to highlight health disparities among former combatants

American Journal of Public Health special issue to highlight health disparities among former combatants -

In an online-only, open access special issue of American Journal of Public health , the researchers study health equity issues, quality and disparities within the veterans health care system.

"As one of the largest integrated health care systems, we remember the access and quality in our daily mission statement - 'to care for him who carried the battle, or his widow, and his orphan. However, we realized that some veterans, especially those having characteristics related to discrimination and social exclusion, continue to experience disparities in access and equitable care, " writes Robert Jesse, MD, PhD, former acting undersecretary for health of the Administrator of veterans health Affairs.

"A failure in the quality of care, access or fairness is the antithesis of our duty to those who have served to protect our freedoms ;. it's just not who we are as a organization "
accompanying the 11 research papers are a collection of editorials and memories taking on subjects including the gender, race and genomics, social determinants of equity health care and transgender veteran.

documents of this issue will be freely available online on 6 August. 2014-12 EDT

Highlights of the special issue of the American Journal of Public Health include:
1.Veterans show increase making smokeless houses but lag behind civilians
2.Racial disparities observed in cancer patients receiving care in the VA health care system
3.Suicidal ideation and mental distress correlated with those in their forties with military history

veterans show increase making the smoke houses, but still lagging behind civilians
a new study from the American Journal of public Health concludes that veterans but showing an increase between 01 and 2011, remain non-veterans behind to voluntarily adopt rules without smoke in their home. During this time period, the disparity between veterans and non-veteran adoption of smoke-free rules also expanded.

Using Data smoking Supplement 01-02 and 2010-2011 to the Survey of the current population, researchers analyzed patterns Veterans adopting rules of the house without smoke between 01 and 2011 house rules smokeless, noted that the rules voluntarily made by the inhabitants of a household or owner, have been defined as one respondent stating that "no one is allowed to smoke anywhere inside [their] house" within this study.

the results of the study indicated that veterans have shown an increase of the adoption of rules of origin smokeless between 01 and 2011 from 64 percent to 79.7 Veterans percent. This increase, however, does not match the habits of the house without smoke non-veterans who have shown an increase of 67.6 percent with a smoke-free home in 01 to 84.4 percent in 2011. In addition, Smoking prevalence among veterans was found to be higher fighters and former smokers have been found to smoke more than non-veterans who smoke.

"because of high rates of smoking and suboptimal rules at home smokeless rate, we recommend that all Department of Veteran Affairs Patient screening status smokeless home rule and advised to establish comprehensive smoke-free home rules, especially those of smoking households, "the study suggests.

racial disparities observed in cancer patients receiving health care system VA care
A new study from the American Journal of Public Health found the presence of disparities race in cancer treatment and outcomes among older black and white veterans who receive care against cancer for the interior of the veterans health care system.

researchers examined data registry VA Central Cancer from 01 to 04 and VA administrative data from 00 to 05. They also used data and information from the National Death Index 00 Census to 05 . VA cancer patients spanned 118 VA medical centers where the study evaluated 20 process and outcome measures related to cancer to investigate potential racial disparities in cancer patients white and black veterans.

The results showed that for 13 of the 20 measures of quality, black and white patients received similar treatments. However, seven of the 20 measures, racial disparities exist where blacks were lower quality of care. Measures affected by the black included racial disparities with lower rates of early-stage colon cancer diagnosis, three-year survival for cancer of the colon and rectum, curative surgery for early stage lung cancer and Phase I , II and III rectal cancer, among other measures.

"Previous research indicates that racial / ethnic disparities in care and outcomes exist for many conditions, but that these disparities are mitigated in the health care system for veterans," the authors explain .

"Future efforts should focus on understanding the sources of these disparities in the hospital. However, differential models in the adoption of new technologies and the use of drugs through the VA hospitals are potential sources of cancer disparities that deserve further exploration, "they conclude.

People in their forties with military history may be at greater risk for suicidal ideation and mental distress
military service history is associated with suicidal ideation and mental distress among people aged 40 to 64, according to a new study from the American Journal of public Health.

researchers examined data from the Centers for Disease Control and 2010 Behavioral Risk Factor Surveillance System implementation, including data from five states last year inquired suicidal ideation in 2010 represents a sample size of 26,685 people. The study examined the prevalence of suicidal ideation and mental distress in adults with a history of military service.

The results of the study indicated that mental distress last year and suicidal ideation were correlated with the military service history in old elderly 40-64.

"Reasons for an increased prevalence of suicidal ideation last year in people with military experience in midlife (age 40-64) are not clear. It may possibly be a phenomenon related to a cohort effect, an effect of the service era, or both, "the study suggests

Find a complete list of documents to be published online August 6, 2014 at 12:00 below :.
• towards the elimination of health disparities in veterans through the quality, access and equity
• Institutional Journey in Pursuit of Health Equity: Office of Veterans Health Administration health equity
• the struggle for health equity: the sustained effort by the VA
health system • Editorial - of social equity in health determinants
• partnership, research, and leadership to advance health equity and eliminate health disparities
• Race and genomics in the Veterans health administration
• health equity research in the Veterans health administration - We have come far, but are not there yet
• excellence and equality in health care
• improving trends in gender disparities in the Department of Veterans Affairs: 08-2013
• Access to health care for former combatants in transgender HAV: 06-2013
• Suicidality among veterans: Implications of sexual minority status
• ancient American and Asian fighters and soldiers Pacific islands United States: the use of health services and perceived barriers to mental health services
• Understand How to improve the delivery of culturally competent services to American Indians and Alaska Native former combatants address disparities healthcare
• impact of race / ethnicity and sex on hepatitis C Virus and screening prevalence among US Veterans at Veterans Affairs care
• racial disparities in care cancer in the health care system for veterans and the role of care site
• Battling smoking at home: analysis home smokeless us Rules of former combatants 01-2011
• abandonment tobacco in African-American and white smokers in the health system of veterans
• Keep homeless veterans in outpatient care: A mobile pilot study appointment of text message reminders
• l suicidal ideation and psychological distress in adults with military service history: results of the 5 American States, 2010
• Suicidality Prevalence among former combatants Hispanic and African-American after
• Can surgery -on fight against health inequalities and the health of populations without addressing the root causes? An in-silico experiment
• The feasibility and effectiveness of a smoking cessation intervention in a community-based racial, Smoker Urban Cohort